Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Destiny Pharma PLC
DESTDestiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom. Address: Sussex Innovation Centre, Brighton, United Kingdom, BN1 9SB
Analytics
Objectif de Cours de WallStreet
3 474.31 GBXRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés DEST
Analyse des dividendes DEST
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes DEST
Valorisation des titres DEST
financières DEST
Résultats | 2019 | Dynamique |